FOSL1 and neoplasm: BRCA1-deficient tumor cells treated with Akt inhibitor AZD5363 notably inhibited estrogen-enhanced expression of p-4Ebp1, p-mTor, and p-Gsk3 β, as well as Vim (EMT marker) and p-Fra1 (EMT-inducing transcription factor) expression, suggesting that AZD5363 efficiently suppresses estrogen-enhanced Akt pathway and EMT program in BRCA1-deficient tumor cells.